Labels:monitor | sky | window OCR: Enoxaparin in Non-STE ACS ESSENCE trial 3171 pts with CP and ECG changes or h/o CAD enoxaparin 1mq/ka bs bid VS UFH combined endpoin death MI 1 recurreni angina 16% risk reduction enoxaparir FOUE iavs benefit maintained 30 ca no bleeding differences combinec endpoint recurrent reductior group days oleedinc
(.png)
